KLRS

Business Context and Reporting Period

Company: Kalaris Therapeutics, Inc. (KLRS)
Reporting Period: Quarter ended March 31, 2025
Business Overview: Kalaris is a clinical-stage biopharmaceutical company focused on developing TH103, a novel anti-VEGF therapeutic for retinal diseases. The company operates as a single segment.
Material Event: On March 18, 2025, the company consummated a reverse recapitalization merger with AlloVir, Inc. Legacy Kalaris became the accounting acquirer. The combined entity changed its name to Kalaris Therapeutics, Inc. and began trading on the Nasdaq Global Market under the symbol "KLRS."

Key Financial Metrics

Note: Q1 2025 results include the impact of the Merger, including the acquisition of approximately $102.1 million in cash from AlloVir.

Material Changes vs. Prior Period

• Liquidity Surge: Cash and cash equivalents increased from $1.6 million at December 31, 2024, to $101.0 million at March 31, 2025, primarily due to the $102.1 million cash acquired in the Merger with AlloVir.
• Expense Increase: Total operating expenses rose to $10.4 million from $2.6 million in the prior year quarter.
  • R&D Expenses: Increased to $6.0 million (from $2.0 million) driven by the initiation of the Phase 1 clinical trial for TH103, increased CRO/CDMO costs, and personnel hiring.
  • G&A Expenses: Increased to $4.3 million (from $0.6 million) due to legal/accounting fees, D&O insurance costs recognized post-merger, and infrastructure investments.
• Debt Elimination: All outstanding convertible promissory notes and derivative liabilities were converted into equity or cancelled in connection with the Merger. As of March 31, 2025, the company has no outstanding convertible notes.
• Equity Structure: All redeemable convertible preferred stock was converted to common stock. The company now has 18.7 million shares of common stock outstanding.

Guidance, Outlook, and Risks

Outlook and Guidance

• Cash Runway: Management expects existing cash resources ($101.0 million) to fund operations into the fourth quarter of 2026.
• Clinical Milestones: The company is enrolling patients in an open-label Phase 1 trial of TH103 for neovascular Age-related Macular Degeneration (nAMD). Initial clinical data from Part 1 is expected in Q4 2025.
• Future Funding: The company anticipates needing substantial additional funding for future operations and product development.

Management Commentary

Management highlighted the successful integration of the Merger and the strategic focus on TH103. They noted that the company has incurred significant losses since inception and expects to continue doing so until commercialization.

Risks and Contingencies

• Internal Controls: The company identified material weaknesses in its internal control over financial reporting as of March 31, 2025. Disclosure controls and procedures were deemed ineffective. Remediation plans include recruiting additional accounting personnel and implementing new systems.
• Litigation:
  • Securities Class Action: A settlement of $1.0 million was reached regarding legacy AlloVir litigation (Zerbato v. AlloVir), pending court approval.
  • Merger Litigation: Two individual complaints have been filed challenging the Merger proxy statement/prospectus.
• Related Party Obligations: A $32.1 million royalty obligation to Samsara BioCapital L.P. (majority stockholder) is recorded as a long-term liability. No interest expense was recognized in Q1 2025 as payments were not deemed probable.
• Regulatory & Market Risk: Risks include potential FDA workforce reductions, trade tariffs, and the high uncertainty of clinical trial outcomes.

Investor Verification Checklist

• Merger Integration: Verify the timeline and cost of integrating AlloVir's operations and the realization of anticipated synergies.
• Internal Control Remediation: Monitor the progress of hiring a CFO and implementing controls to address the identified material weaknesses.
• Cash Burn Rate: Track quarterly operating cash burn against the $101 million cash balance to validate the Q4 2026 runway estimate.
• Clinical Trial Progress: Confirm patient enrollment rates and safety data for the TH103 Phase 1 trial.
• Litigation Status: Monitor the final court approval of the $1.0 million securities class action settlement and the status of merger-related lawsuits.
• Royalty Liability: Review future assessments of the $32.1 million royalty obligation to Samsara and potential accretion of interest.